Sequencing therapy in advanced prostate cancer: Focus on sipuleucel-T

David I. Quinn, Ulka Vaishampayan, Celestia S. Higano, Daniel W. Lin, Neal D. Shore, Tomasz (Tom) Beer

    Research output: Contribution to journalArticle

    4 Citations (Scopus)

    Abstract

    Immunotherapies such as sipuleucel-T present new and unique challenges for the optimal timing and sequencing of therapies for metastatic castration-resistant prostate cancer (mCRPC). Key considerations for the sequencing of sipuleucel-T are its unique proposed mechanism of action, the time required to generate a clinically relevant immune response, and the observed efficacy in Phase III trials in 'early' or asymptomatic or minimally symptomatic mCRPC. There are three broad timing and sequencing options for sipuleucel-T in patients with rising prostate-specific antigen and radiologic evidence of disease: immediately after androgen-deprivation therapy failure, after failure of secondary hormonal maneuvers, or after chemotherapy. There are several other agents in Phase III development in mCRPC and any future approvals will impact on the current treatment algorithm, and raise further questions regarding how to optimize sequencing and timing of therapies for better clinical outcomes.

    Original languageEnglish (US)
    Pages (from-to)51-61
    Number of pages11
    JournalExpert Review of Anticancer Therapy
    Volume14
    Issue number1
    DOIs
    StatePublished - Jan 2014

    Fingerprint

    Castration
    Prostatic Neoplasms
    Therapeutics
    Prostate-Specific Antigen
    Immunotherapy
    Androgens
    Drug Therapy
    sipuleucel-T

    Keywords

    • abiraterone
    • drug therapy
    • early detection of cancer
    • enzalutamide
    • immunotherapy
    • ipilimumab
    • neoplasm metastasis
    • prostatic neoplasms
    • radium-223
    • sipuleucel-T

    ASJC Scopus subject areas

    • Pharmacology (medical)
    • Oncology

    Cite this

    Sequencing therapy in advanced prostate cancer : Focus on sipuleucel-T. / Quinn, David I.; Vaishampayan, Ulka; Higano, Celestia S.; Lin, Daniel W.; Shore, Neal D.; Beer, Tomasz (Tom).

    In: Expert Review of Anticancer Therapy, Vol. 14, No. 1, 01.2014, p. 51-61.

    Research output: Contribution to journalArticle

    Quinn, David I. ; Vaishampayan, Ulka ; Higano, Celestia S. ; Lin, Daniel W. ; Shore, Neal D. ; Beer, Tomasz (Tom). / Sequencing therapy in advanced prostate cancer : Focus on sipuleucel-T. In: Expert Review of Anticancer Therapy. 2014 ; Vol. 14, No. 1. pp. 51-61.
    @article{4d14aaf7b09848a3af56ed248fa747f3,
    title = "Sequencing therapy in advanced prostate cancer: Focus on sipuleucel-T",
    abstract = "Immunotherapies such as sipuleucel-T present new and unique challenges for the optimal timing and sequencing of therapies for metastatic castration-resistant prostate cancer (mCRPC). Key considerations for the sequencing of sipuleucel-T are its unique proposed mechanism of action, the time required to generate a clinically relevant immune response, and the observed efficacy in Phase III trials in 'early' or asymptomatic or minimally symptomatic mCRPC. There are three broad timing and sequencing options for sipuleucel-T in patients with rising prostate-specific antigen and radiologic evidence of disease: immediately after androgen-deprivation therapy failure, after failure of secondary hormonal maneuvers, or after chemotherapy. There are several other agents in Phase III development in mCRPC and any future approvals will impact on the current treatment algorithm, and raise further questions regarding how to optimize sequencing and timing of therapies for better clinical outcomes.",
    keywords = "abiraterone, drug therapy, early detection of cancer, enzalutamide, immunotherapy, ipilimumab, neoplasm metastasis, prostatic neoplasms, radium-223, sipuleucel-T",
    author = "Quinn, {David I.} and Ulka Vaishampayan and Higano, {Celestia S.} and Lin, {Daniel W.} and Shore, {Neal D.} and Beer, {Tomasz (Tom)}",
    year = "2014",
    month = "1",
    doi = "10.1586/14737140.2014.848065",
    language = "English (US)",
    volume = "14",
    pages = "51--61",
    journal = "Expert Review of Anticancer Therapy",
    issn = "1473-7140",
    publisher = "Expert Reviews Ltd.",
    number = "1",

    }

    TY - JOUR

    T1 - Sequencing therapy in advanced prostate cancer

    T2 - Focus on sipuleucel-T

    AU - Quinn, David I.

    AU - Vaishampayan, Ulka

    AU - Higano, Celestia S.

    AU - Lin, Daniel W.

    AU - Shore, Neal D.

    AU - Beer, Tomasz (Tom)

    PY - 2014/1

    Y1 - 2014/1

    N2 - Immunotherapies such as sipuleucel-T present new and unique challenges for the optimal timing and sequencing of therapies for metastatic castration-resistant prostate cancer (mCRPC). Key considerations for the sequencing of sipuleucel-T are its unique proposed mechanism of action, the time required to generate a clinically relevant immune response, and the observed efficacy in Phase III trials in 'early' or asymptomatic or minimally symptomatic mCRPC. There are three broad timing and sequencing options for sipuleucel-T in patients with rising prostate-specific antigen and radiologic evidence of disease: immediately after androgen-deprivation therapy failure, after failure of secondary hormonal maneuvers, or after chemotherapy. There are several other agents in Phase III development in mCRPC and any future approvals will impact on the current treatment algorithm, and raise further questions regarding how to optimize sequencing and timing of therapies for better clinical outcomes.

    AB - Immunotherapies such as sipuleucel-T present new and unique challenges for the optimal timing and sequencing of therapies for metastatic castration-resistant prostate cancer (mCRPC). Key considerations for the sequencing of sipuleucel-T are its unique proposed mechanism of action, the time required to generate a clinically relevant immune response, and the observed efficacy in Phase III trials in 'early' or asymptomatic or minimally symptomatic mCRPC. There are three broad timing and sequencing options for sipuleucel-T in patients with rising prostate-specific antigen and radiologic evidence of disease: immediately after androgen-deprivation therapy failure, after failure of secondary hormonal maneuvers, or after chemotherapy. There are several other agents in Phase III development in mCRPC and any future approvals will impact on the current treatment algorithm, and raise further questions regarding how to optimize sequencing and timing of therapies for better clinical outcomes.

    KW - abiraterone

    KW - drug therapy

    KW - early detection of cancer

    KW - enzalutamide

    KW - immunotherapy

    KW - ipilimumab

    KW - neoplasm metastasis

    KW - prostatic neoplasms

    KW - radium-223

    KW - sipuleucel-T

    UR - http://www.scopus.com/inward/record.url?scp=84893037371&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84893037371&partnerID=8YFLogxK

    U2 - 10.1586/14737140.2014.848065

    DO - 10.1586/14737140.2014.848065

    M3 - Article

    C2 - 24224900

    AN - SCOPUS:84893037371

    VL - 14

    SP - 51

    EP - 61

    JO - Expert Review of Anticancer Therapy

    JF - Expert Review of Anticancer Therapy

    SN - 1473-7140

    IS - 1

    ER -